NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced new positive coverage decisions from Geisinger Health Plan and Emblem Health, expanding access to the UroLift® System for the treatment of their members with benign prostatic hyperplasia (BPH).
Geisinger Health Plan, one of the nation’s largest integrated health services organizations, has approximately 540,000 members primarily in Pennsylvania and with a notable presence across south New Jersey, Delaware, Maine and West Virginia. Emblem Health, in New York, New Jersey and Connecticut, issued its coverage policy for the plan’s Medicare Advantage members.
“We are pleased to see the continued expansion of access to UroLift for millions of men across the United States who are seeking this much less invasive treatment for BPH,” said Dave Amerson, president and CEO, NeoTract, Inc. “That integrated healthcare systems such as Geisinger, Kaiser Permanente, and Select Health have all embraced UroLift system treatment is not only a testament to the improved net health outcomes UroLift offers, but also the efficiency of care the treatment can provide a healthcare system.”
The UroLift System is a first-line treatment that gets men off BPH medications and allows them to avoid major surgery, while preserving sexual function. Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to transurethral resection of the prostate (TURP) with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.
Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life. Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.UroLift.com.
For NeoTract, Inc.:
MAC00348-01 Rev A